SPOTLIGHT: Better times ahead for BMS?

With its two-year federal probationary period coming to an end, the Wall Street Journal reports that the dark clouds may be lifting from Bristol-Myers Squibb. An earnings report from BMS is due on Thursday, and analysts are expecting some word on the company's search for a new CEO. Investors are also looking for some insight into the damage done by the temporary sale of a generic competitor to Plavix. Report (WSJ sub. req.)